Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy Japanese male subjects~Exclusion criteria:~1. Any relevant deviation from healthy conditions

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Idarucizumab single doses (Type: EXPERIMENTAL): different infusion durations
- Idarucizumab with dabigatran (Type: EXPERIMENTAL): short infusion with 2 capsules dabigatran

Based on this trial design, predict the completion outcome and termination type (if applicable).